How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
ADME/Tox Technologies Market
- By Technology Type: In Vitro ADME Assays, In Vivo ADME Studies, In Silico ADME Modeling, Toxicokinetics Analysis, High-Throughput Screening Technologies
- By Application: Drug Metabolism Studies, Toxicity Testing, Pharmacokinetics Profiling, Safety Assessment, Biomarker Discovery
- By End User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic and Research Institutes, Regulatory Agencies
- By Assay Format: Cell-Based Assays, Microsomal Stability Assays, Enzyme Inhibition Assays, Animal Models, Computational Simulations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In Vitro ADME Assays leads By Technology Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the ADME/Tox Technologies Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Technology Type 5
Application 5
End User 5
Assay Format 5
Companies profiled
Charles River Laboratories International Inc.
Eurofins Scientific
Covance Inc. (LabCorp)
WuXi AppTec
PRA Health Sciences
ICON plc
Q2 Solutions
BioIVT
Envigo
Frontage Laboratories Inc.
Absorption Systems
LLC
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Covance Inc. (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PRA Health Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Q2 Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BioIVT
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Envigo
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Frontage Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Absorption Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pharmaron
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Toxikon Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Evotec SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →SRI International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,303M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In Vitro ADME Assays45.8
- In Vivo ADME Studies11.6
- In Silico ADME Modeling14.6
- Toxicokinetics Analysis14.0
- High-Throughput Screening Technologies13.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,478M → $2,859M · 8.6%
Europe$1,030M → $2,176M · 9.8%
Asia Pacific$940.7M → $1,918M · 9.3%
Latin America$582.4M → $1,261M · 10.1%
Middle East and Africa$448.0M → $866.0M · 8.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.522026
9.532027
9.542028
9.552029
9.572030
9.582031
9.602032
9.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.21.4
- Eurofins Scientific9.4
- Covance Inc. (LabCorp)9.9
- WuXi AppTec7.9
- PRA Health Sciences9.7
- ICON plc13.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology Type29.3%
Application29.2%
End User28.0%
Assay Format13.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.5
- Europe24.0
- Asia Pacific21.1
- Latin America13.9
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 76 | 78 | 89 | 91 | 80 | 77 | 82 |
| Eurofins Scientific | 85 | 90 | 77 | 92 | 86 | 75 | 84 |
| Covance Inc. (LabCorp) | 82 | 67 | 68 | 84 | 71 | 76 | 75 |
| WuXi AppTec | 72 | 82 | 64 | 73 | 80 | 67 | 73 |
| PRA Health Sciences | 72 | 72 | 56 | 59 | 68 | 71 | 66 |
| ICON plc | 47 | 54 | 66 | 68 | 53 | 54 | 57 |
| Q2 Solutions | 55 | 65 | 53 | 42 | 50 | 58 | 54 |
| BioIVT | 52 | 42 | 43 | 58 | 55 | 41 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Eurofins Scientific
- Covance Inc. (LabCorp)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Eurofins Scientific | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Covance Inc. (LabCorp) | ◐ | ◐ | ◐ | ✓ | ✓ | − |
| WuXi AppTec | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| PRA Health Sciences | ✓ | ✓ | − | − | ◐ | ◐ |
| ICON plc | − | − | ◐ | ◐ | − | ◐ |
| Q2 Solutions | − | ◐ | ◐ | ◐ | − | ◐ |
| BioIVT | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eurofins Scientific84
2Charles River Laboratories International Inc.82
3Covance Inc. (LabCorp)75
4WuXi AppTec73
5PRA Health Sciences66
6ICON plc57
7Q2 Solutions54
8BioIVT49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Eurofins Scientific
Challenger2
Strong scale, closing on the leaders.
Covance Inc. (LabCorp)WuXi AppTec
Contender2
Focused players with pockets of strength.
PRA Health SciencesICON plc
Niche2
Specialists in a single segment or region.
Q2 SolutionsBioIVT
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology Type in North America, then scale across ADME/Tox Technologies Market — a $302M beachhead inside a $4.68B market.
Beachhead (SOM)$302Mobtainable near-term
Serviceable (SAM)$1.72Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
In Vitro ADME Assays
Best fit — highest urgency & budget in Technology Type.
Economic buyer78 fit
In Vivo ADME Studies
Strong fit — clear ROI and a fast path to value.
End user68 fit
In Silico ADME Modeling
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Technology Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win ADME/Tox Technologies Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation12%
Closed-won8%
$10.9KCAC
$61KLTV
5.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
ADME/Tox Technologies Market is a durable-growth opportunity — $2.45B by 2033, compounding at 7.3%.
TAM · 2025$1.40Btoday
TAM · 2033$2.45Bforecast
CAGR7.3%2027–2033
Cumulative$16.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.45BTotal addressable market
SAM$1.02BServiceable available market
SOM$197MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.3% CAGR
Demand compounds through 2033, outpacing GDP across Technology Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.45BLarge & growingTAM by 2033 at 7.3% CAGR
$1.02BServiceable nowreachable with today’s model
$197MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.91BBear4.7% CAGR
$2.45BBase7.3% CAGR
$3.14BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
ADME/Tox Technologies Market — a $4.50B market by 2033. Plan: grow share from 10.2% to 18.8%.
Market size · 2033$4.50Btotal addressable
Market CAGR10.6%2027–2033
Target share18.8%from 10.2% today
Revenue ambition$846Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.2% | 18.8% | At risk |
| Revenue | $503M | $846M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.6% | 41.3% | At risk |
| Customer retention | 86.2% | 96.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $123M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Technology Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the ADME/Tox Technologies Market conversation — a $7.60B market you can size, segment and defend in minutes.
Market size · 2033$7.60Btotal opportunity
Growth6.3%CAGR to 2033
Addressable buyers1,388+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology Type
Goal Grow share in Technology Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 4 mopayback period
$81K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Eurofins ScientificCovance Inc. (LabCorp)WuXi AppTecPRA Health SciencesICON plcQ2 SolutionsBioIVT+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your ADME/Tox Technologies Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
ADME/Tox Technologies Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Admission & Enrollment Management Software Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportAdrenal Cancer Diagnostics Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAdrenaline Acid Tartrate Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAdrenaline Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAdrenaline Oxygen Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAdrenaline Tartrate Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAdrenalone Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAdrenochrome Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAdrenocortical Carcinoma Drug Market
Market size, share, segmentation and regional forecast.
$320M market · 2025 base year
View reportAdrenocortical Carcinoma Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAdrenoleukodystrophy Drug Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAdrenoleukodystrophy Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.